Jennerex's Nexavar rival Pexa-Vec shows promising Phase II efficacy in HCC
This article was originally published in Scrip
Jennerex published data from a 30-patient Phase II dose comparison study for Pexa-Vec (JX-594) - an oncolytic virus engineered as an immunotherapy - which show the highest dose administered to patients with advanced hepatocellular carcinoma (HCC) may outperform the Bayer and Onyx Pharmaceuticals liver cancer drug Nexavar (sorafenib).
You may also be interested in...
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.